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THE value of CD30 and the soluble circulating frag-
ment of CD30 (sCD30) for atopic dermatitis (AD)
remains unclear. In particular, little is known about
the effects of age, duration of disease and Scoring
Atopic Dermatitis index (SCORAD) on the levels of
serum sCD30 in patients affected by AD.
In the present study, we have analysed serum sCD30
levels of adult patients affected by AD. The study’s
population includes 18 non-smoking outpatients,
with a diagnosis of AD. As a control group we studied
18 non-atopic subjects from laboratory staff, matched
for sex and age. These subjects had no history of AD,
urticaria or seasonal or perennial rhinitis or asthma,
and had negative skin prick test to a panel of
allergens.
The sCD30 serum levels were clearly higher in
patients affected by AD (14.29 /9.0 IU/ml) than in
healthy subjects (1.29 /0.8 IU/ml) (p B/0.001). No
differences were observed between males and fe-
males affected by atopic dermatitis, regarding age,
duration of disease and SCORAD. Significant correla-
tions were found between serum levels of sCD30
levels and age (r/ /0.55; 95% confidence interval
(CI) for r (Fisher’s z transformed)/ /0.81 to  /0.12;
p/0.01), duration of the disease (months) (r/ /
0.64; 95% CI for r (Fisher’s z transformed)/ /0.85
to  /0.24; p/0.004) and SCORAD (r/ /0.74; 95% CI
for r (Fisher’s z transformed)/ /0.89 to  /0.42; p/
0.004).
As demonstrated by the close correlation with age,
duration of disease and SCORAD, serum levels of
sCD30 appear to be an additional marker for the
follow-up of AD.
Key words: Atopic dermatitis, Serum sCD30, SCORAD
Mediators of Inflammation, 12(2), 123/125 (April 2003)
Serum levels of soluble CD30 in
adult patients affected by atopic
dermatitis and its relation to age,
duration of disease and Scoring
Atopic Dermatitis index
Gabriele Di Lorenzo
1, Sebastiano Gangemi
2,
Rosaria Alba Merendino
2, Paola Lucia Minciullo
2,
Seraﬁna Paola Cannavo `
3, Nicola Martinelli
4,
Pasquale Mansueto
1, Giovanni Battista Rini
1,
Roberto Corrocher
4 and Maria Luisa Pacor
4,CA
1Dipartimento di Medicina Clinica e delle Patologie
Emergenti, Universita ` degli Studi di Palermo, Italy;
2Dipartimento di Patologia Umana, Universita ` degli
Studi di Messina, Italy;
3Dipartimento di Medicina
Sociale Territoriale, Universita ` degli Studi di Messina,
Italy
4Dipartimento di Medicina Clinica e
Sperimentale, Universita ` degli Studi di Verona,
Sezione B / Policlinico GB Rossi, Piazzale Scuro 10,
37134 Verona, Italy
CACorresponding author
Fax:  /39 45 580111
E-mail: marialuisa.pacor@univr.it
Introduction
CD30 is a member of the tumour necrosis factor/
nerve growth factor (TNF-NGF) receptor superfamily
existent as a membrane glycoprotein of 105 and 120
kDa, derived from a 90 kDa precursor, and a 57 kDa
intracellular form. CD30 is considered a marker of
activated T helper (Th)0/Th2 lymphocytes, which are
key cells in the pathogenesis of allergic diseases.
1
However, in some diseases with a predominance of
Th1 cells (i.e. in rheumatoid arthritis), there is also a
presence of CD30 / T cells.
2 The membrane mole-
cule can be transformed into a soluble form (sCD30)
by limited proteolysis (i.e. shedding) as well as the
cytokine receptors, and then can be detected in
biological fluids, including serum.
1
Atopic dermatitis (AD) is a skin disorder that arises
as a result of the interaction of environmental factors
with an abnormal immune system in a genetically
predisposed individual.
3
Immunological defects in both humoral and cel-
lular response are present in AD.
3 Indeed, it is
possible to find high amounts of immunoglobulin
E, eosinophil cationic protein, soluble interleukin
(IL)-2 receptor, soluble CD23 and some adhesion
molecules in sera of patients affected by AD.
4,5
Recently, studies on eczematous skin diseases, such
as AD, have focused on T-cell-mediated immune
effector mechanisms.
6 The abnormalities in cytokine
production typical of AD are linked to an imbalance
between Th1 and Th2 cells.
3 Indeed, high levels of
Th2-type cytokines, such as IL-4 and IL-5, are
produced by T cells that are isolated from skin
biopsies and are found in the supernatant of periph-
eral blood lymphocytes.
7 On the other hand, inter-
feron (IFN)-g is less produced by T cells of patients
with severe AD than by T cells from healthy donors.
This deficiency of IFN-g is not restored by IL-2, IL-15
and IL-18.
8
Allergen-reactive Th0/Th2-like cells expressing
membrane CD30 are present in the circulation of
AD patients. Moreover, in patients affected by AD, it
is possible to find CD30 / T cells and high sCD30
levels are present in the serum of atopic patients.
9
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123However, recent data have shown that the T-cell-line
unstimulated cultures of patients with AD expressed
a Th1 profile. After stimulation with anti-CD3 and
anti-CD28 monoclonal antibodies, the cytokine ex-
pression showed rapid initial up-regulation of Th2
followed by a Th1 profile. Therefore, skin T lympho-
cytes from AD patients seem to consist of a hetero-
geneous population of Th1 and Th2 or Th0 cells.
10
Moreover, work by Tanaka, using in situ hybridisa-
tion, elucidated mRNA expressions of both Th1 and
Th2 cytokine in the lesions of AD.
11
In the present study, we have analysed serum
sCD30 levels in adult patients affected by AD and its
relation to age, duration of disease, and Scoring
Atopic Dermatitis index (SCORAD).
Materials and methods
A group of 18 non-smoking outpatients (nine males
and nine females; aged 13/39 years; mean age,
23.89 /8.6 years) with clinical diagnosis of AD has
been studied. At the time of the study, none of
patients was receiving steroid or immunosuppres-
sants. The severity of dermatitis was evaluated
according to SCORAD.
12 Briefly, SCORAD defines a
score for three parameters: extent, intensity and
subjective symptoms. The extent of the lesions is
calculated with the rule of nines and indicates the
body surface involved. Intensity items are erythema,
oedema/papulation, oozing/crusts, excoriations, li-
chenification and dryness of non-involved skin (0/3
points for each item). Subjective symptoms
are itching and sleep loss (0/10 points for each
item). The total score is calculated according to
the following equation: SCORAD/(0.2/area) /
[3.5/(eritema /oedema/papulation /oozing/crusts
 /excoriations /lichenification /dry skin)] /subjec-
tive score. Index scores of disease’s severity range
from 0 to 103.
As a control group we studied 18 non-atopic
subjects from laboratory staff (10 males and eight
females; aged 18/41 years; mean age, 25.19 /7.9
years). They had no history of AD, seasonal or
perennial rhinitis, asthma, or urticaria, and had
negative skin prick test to a panel of allergens. Blood
samples were draw in Vacutainer SST tubes and, after
allowing clotting for 60 min at room temperature, the
blood was centrifuged at 1300/g for 10 min at room
temperature. The sera were frozen at  /708C and
analysed at the end of the study period.
Serum sCD30 levels were measured by a sandwich
enzyme-linked immunoassay CD30 (Dako, Milan,
Italy). The assay was performed according to the
manufacturer’s instruction and expressed as interna-
tional units per millilitre. The detection limit of the
assay was 1 IU/ml.
Data were expressed as the mean9 /standard
deviation. An unpaired t-test was used to compare
the difference between the groups. Simple regression
analysis was used to assess the correlation between
serum sCD30 levels and age, duration of disease and
SCORAD.
Results
Serum levels of sCD30 in patients affected by AD
(14.29 /2.1 U/ml) were significantly higher than those
observed in healthy subjects (versus 1.19 /0.2 IU/ml)
(pB/0.001). No significant age-dependent influence
on the serum sCD30 levels was observed in patients
and in the control set (data not shown).
No differences between males and females affected
by AD were found for age, duration of the disease,
SCORAD and levels of serum sCD30 (Table 1).
As shown in Fig. 1A/C, significant correlations
were found between serum levels of sCD30 levels
and age (r/ /0.55; 95% confidence interval for r
(Fisher’s z transformed)//0.81 to  /0.12; p/0.01),
duration of the disease (months) (r/ /0.64; 95% CI
for r (Fisher’s z transformed)/ /0.85 to  /0.24; p/
0.004), and SCORAD (r/ /0.74; 95% CI for r (Fish-
er’s z transformed)/ /0.89 to  /0.42; p/0.004).
Discussion
AD is a chronic allergic inflammatory disease that
manifests itself as eczematous skin lesions.
3 Both Th1
and Th2 cells are involved in AD. A recent study
suggested that the relative contribution of Th1-type
and Th2-type cytokines to the pathogenesis of AD
depends on the duration of the eruption.
3 It has been
demonstrated, by in situ hybridization, that acute
skin lesions had larger numbers of cells that were
positive for IL-4, IL-5, and IL-13 mRNA, whereas they
contained few IFN-g-positive cells, compared with
normal control skin.
13 Comparing acute AD with
chronic AD skin lesion revealed significantly lower
number of IL-4 and IL-13 mRNA-positive cells but
increased numbers of IL-5 and IFN-g-positive cells.
Other studies confirmed that an increased in situ
expression of Th2-type cytokines IL-4 and IL-10 was
always observed together with increased expression
of Th1-type cytokine IFN-g within identical chronic
Table 1. Comparison between males and females affected
by AD
Males (n/9) Females (n/9) p
Age (years) 23.79 /7.8 24.09 /9.8 0.9
Onset of AD (months) 186.69 /95.5 126.59 /86.6 0.1
SCORAD index 36.79 /14.4 32.79 /14.5 0.6
Serum sCD30 11.09 /8.3 17.39 /8.9 0.1
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14,15 These findings
indicate that in the acute phase AD is driven by Th2
cells, while in the chronic phase AD is driven by both
Th1 and Th2 cells. We found significantly higher
levels of sCD30 in serum obtained from AD patients
compared with healthy non-atopic controls. The
most important finding of this study was that serum
sCD30 levels are negatively correlated with age and
duration of disease. It is therefore suggested that the
chronic phase of AD is associated with down-regula-
tion of Th2 cells. This implies that the highest
SCORAD are related to a down-regulation Th2 cells.
In conclusion, the present data are consistent with
the hypothesis that chronic AD is predominantly
driven by activated Th1 cells and the aggravation of
AD is accompanied by up-activation of Th2 cells.
Serum sCD30 may be a useful circulating marker as
far as the choice of the treatment of AD is concerned.
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FIG. 1. (A) Correlation between serum sCD30 and age (years)
(r/ /0.55; 95% CI for r (Fisher’s z transformed)/ /0.81 to  /
0.12; p/0.01). (B) Correlation between serum sCD30 and
duration of disease (months) (r/ /0.64; 95% CI for r (Fish-
er’s z transformed)//0.85 to  /0.24; p/0.004). (C) Correla-
tion between serum sCD30 and SCORAD (r/ /0.74; 95% CI
for r (Fisher’s z transformed)//0.89 to  /0.42; p/0.004).
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